nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylscopolamine bromide—Urinary hesitation—Zidovudine—acquired immunodeficiency syndrome	0.04	0.0418	CcSEcCtD
Methylscopolamine bromide—Urinary hesitation—Lamivudine—acquired immunodeficiency syndrome	0.0285	0.0299	CcSEcCtD
Methylscopolamine bromide—Accommodation disorder—Indinavir—acquired immunodeficiency syndrome	0.0266	0.0278	CcSEcCtD
Methylscopolamine bromide—Ageusia—Ritonavir—acquired immunodeficiency syndrome	0.0157	0.0165	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Nelfinavir—acquired immunodeficiency syndrome	0.012	0.0125	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Indinavir—acquired immunodeficiency syndrome	0.00963	0.0101	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Efavirenz—acquired immunodeficiency syndrome	0.0091	0.00953	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Delavirdine—acquired immunodeficiency syndrome	0.00871	0.00911	CcSEcCtD
Methylscopolamine bromide—Drowsiness—Efavirenz—acquired immunodeficiency syndrome	0.00806	0.00844	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Ritonavir—acquired immunodeficiency syndrome	0.00805	0.00843	CcSEcCtD
Methylscopolamine bromide—Erectile dysfunction—Delavirdine—acquired immunodeficiency syndrome	0.00797	0.00834	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Didanosine—acquired immunodeficiency syndrome	0.00791	0.00828	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Didanosine—acquired immunodeficiency syndrome	0.00775	0.00812	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Saquinavir—acquired immunodeficiency syndrome	0.00775	0.00811	CcSEcCtD
Methylscopolamine bromide—Abdominal distension—Lamivudine—acquired immunodeficiency syndrome	0.00739	0.00774	CcSEcCtD
Methylscopolamine bromide—Erectile dysfunction—Ritonavir—acquired immunodeficiency syndrome	0.00737	0.00771	CcSEcCtD
Methylscopolamine bromide—Erectile dysfunction—Saquinavir—acquired immunodeficiency syndrome	0.00709	0.00742	CcSEcCtD
Methylscopolamine bromide—Tension—Zidovudine—acquired immunodeficiency syndrome	0.00703	0.00736	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Nevirapine—acquired immunodeficiency syndrome	0.00697	0.0073	CcSEcCtD
Methylscopolamine bromide—Nervousness—Zidovudine—acquired immunodeficiency syndrome	0.00696	0.00729	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Stavudine—acquired immunodeficiency syndrome	0.00687	0.00719	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Abacavir—acquired immunodeficiency syndrome	0.00663	0.00694	CcSEcCtD
Methylscopolamine bromide—Tension—Indinavir—acquired immunodeficiency syndrome	0.00654	0.00685	CcSEcCtD
Methylscopolamine bromide—Nervousness—Indinavir—acquired immunodeficiency syndrome	0.00647	0.00678	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Indinavir—acquired immunodeficiency syndrome	0.00628	0.00658	CcSEcCtD
Methylscopolamine bromide—Somnolence—Nevirapine—acquired immunodeficiency syndrome	0.0062	0.00649	CcSEcCtD
Methylscopolamine bromide—Tension—Efavirenz—acquired immunodeficiency syndrome	0.00618	0.00647	CcSEcCtD
Methylscopolamine bromide—Nervousness—Efavirenz—acquired immunodeficiency syndrome	0.00612	0.0064	CcSEcCtD
Methylscopolamine bromide—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.00611	0.00639	CcSEcCtD
Methylscopolamine bromide—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.0061	0.00639	CcSEcCtD
Methylscopolamine bromide—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.00609	0.00637	CcSEcCtD
Methylscopolamine bromide—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.006	0.00628	CcSEcCtD
Methylscopolamine bromide—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.006	0.00628	CcSEcCtD
Methylscopolamine bromide—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.00598	0.00626	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.00594	0.00621	CcSEcCtD
Methylscopolamine bromide—Tension—Delavirdine—acquired immunodeficiency syndrome	0.00591	0.00619	CcSEcCtD
Methylscopolamine bromide—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.0059	0.00618	CcSEcCtD
Methylscopolamine bromide—Palpitations—Indinavir—acquired immunodeficiency syndrome	0.00589	0.00617	CcSEcCtD
Methylscopolamine bromide—Nervousness—Delavirdine—acquired immunodeficiency syndrome	0.00585	0.00613	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.00585	0.00612	CcSEcCtD
Methylscopolamine bromide—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00576	0.00603	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.00574	0.00601	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.00571	0.00598	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.00568	0.00595	CcSEcCtD
Methylscopolamine bromide—Palpitations—Efavirenz—acquired immunodeficiency syndrome	0.00557	0.00583	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.00556	0.00582	CcSEcCtD
Methylscopolamine bromide—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00556	0.00582	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.00555	0.00581	CcSEcCtD
Methylscopolamine bromide—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.00554	0.0058	CcSEcCtD
Methylscopolamine bromide—Tension—Ritonavir—acquired immunodeficiency syndrome	0.00547	0.00572	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.00546	0.00572	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.00544	0.0057	CcSEcCtD
Methylscopolamine bromide—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.00541	0.00567	CcSEcCtD
Methylscopolamine bromide—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00541	0.00566	CcSEcCtD
Methylscopolamine bromide—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00536	0.00561	CcSEcCtD
Methylscopolamine bromide—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00535	0.0056	CcSEcCtD
Methylscopolamine bromide—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00533	0.00558	CcSEcCtD
Methylscopolamine bromide—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.00533	0.00558	CcSEcCtD
Methylscopolamine bromide—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.00529	0.00554	CcSEcCtD
Methylscopolamine bromide—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.00527	0.00551	CcSEcCtD
Methylscopolamine bromide—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00525	0.0055	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00524	0.00549	CcSEcCtD
Methylscopolamine bromide—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.0052	0.00544	CcSEcCtD
Methylscopolamine bromide—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.00518	0.00543	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00514	0.00538	CcSEcCtD
Methylscopolamine bromide—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00505	0.00529	CcSEcCtD
Methylscopolamine bromide—Tension—Lamivudine—acquired immunodeficiency syndrome	0.00502	0.00526	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.00502	0.00525	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00502	0.00525	CcSEcCtD
Methylscopolamine bromide—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.005	0.00524	CcSEcCtD
Methylscopolamine bromide—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.005	0.00524	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00497	0.00521	CcSEcCtD
Methylscopolamine bromide—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.00497	0.0052	CcSEcCtD
Methylscopolamine bromide—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.00496	0.00519	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.00496	0.00519	CcSEcCtD
Methylscopolamine bromide—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00493	0.00516	CcSEcCtD
Methylscopolamine bromide—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.00492	0.00516	CcSEcCtD
Methylscopolamine bromide—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.00492	0.00515	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00488	0.00511	CcSEcCtD
Methylscopolamine bromide—Headache—Didanosine—acquired immunodeficiency syndrome	0.00486	0.00508	CcSEcCtD
Methylscopolamine bromide—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.00484	0.00507	CcSEcCtD
Methylscopolamine bromide—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00484	0.00506	CcSEcCtD
Methylscopolamine bromide—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00483	0.00506	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00482	0.00505	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.0048	0.00503	CcSEcCtD
Methylscopolamine bromide—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00476	0.00498	CcSEcCtD
Methylscopolamine bromide—Constipation—Indinavir—acquired immunodeficiency syndrome	0.00465	0.00487	CcSEcCtD
Methylscopolamine bromide—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.00465	0.00487	CcSEcCtD
Methylscopolamine bromide—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00465	0.00487	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00464	0.00486	CcSEcCtD
Methylscopolamine bromide—Nausea—Didanosine—acquired immunodeficiency syndrome	0.0046	0.00482	CcSEcCtD
Methylscopolamine bromide—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00459	0.0048	CcSEcCtD
Methylscopolamine bromide—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00457	0.00478	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00448	0.00469	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00447	0.00468	CcSEcCtD
Methylscopolamine bromide—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00446	0.00467	CcSEcCtD
Methylscopolamine bromide—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00445	0.00466	CcSEcCtD
Methylscopolamine bromide—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00445	0.00466	CcSEcCtD
Methylscopolamine bromide—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00444	0.00465	CcSEcCtD
Methylscopolamine bromide—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00443	0.00464	CcSEcCtD
Methylscopolamine bromide—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.00441	0.00462	CcSEcCtD
Methylscopolamine bromide—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.0044	0.0046	CcSEcCtD
Methylscopolamine bromide—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00438	0.00459	CcSEcCtD
Methylscopolamine bromide—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00437	0.00458	CcSEcCtD
Methylscopolamine bromide—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00437	0.00457	CcSEcCtD
Methylscopolamine bromide—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00432	0.00452	CcSEcCtD
Methylscopolamine bromide—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00429	0.00449	CcSEcCtD
Methylscopolamine bromide—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00428	0.00448	CcSEcCtD
Methylscopolamine bromide—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00426	0.00446	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00424	0.00443	CcSEcCtD
Methylscopolamine bromide—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00423	0.00443	CcSEcCtD
Methylscopolamine bromide—Headache—Stavudine—acquired immunodeficiency syndrome	0.00422	0.00441	CcSEcCtD
Methylscopolamine bromide—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00422	0.00441	CcSEcCtD
Methylscopolamine bromide—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00421	0.00441	CcSEcCtD
Methylscopolamine bromide—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00421	0.0044	CcSEcCtD
Methylscopolamine bromide—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.0042	0.00439	CcSEcCtD
Methylscopolamine bromide—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.00418	0.00437	CcSEcCtD
Methylscopolamine bromide—Headache—Abacavir—acquired immunodeficiency syndrome	0.00415	0.00435	CcSEcCtD
Methylscopolamine bromide—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00414	0.00433	CcSEcCtD
Methylscopolamine bromide—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00411	0.00431	CcSEcCtD
Methylscopolamine bromide—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00408	0.00428	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00405	0.00424	CcSEcCtD
Methylscopolamine bromide—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00404	0.00423	CcSEcCtD
Methylscopolamine bromide—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00401	0.0042	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00401	0.0042	CcSEcCtD
Methylscopolamine bromide—Nausea—Stavudine—acquired immunodeficiency syndrome	0.004	0.00419	CcSEcCtD
Methylscopolamine bromide—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00396	0.00414	CcSEcCtD
Methylscopolamine bromide—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00394	0.00412	CcSEcCtD
Methylscopolamine bromide—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00391	0.00409	CcSEcCtD
Methylscopolamine bromide—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.0039	0.00409	CcSEcCtD
Methylscopolamine bromide—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00389	0.00407	CcSEcCtD
Methylscopolamine bromide—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00389	0.00407	CcSEcCtD
Methylscopolamine bromide—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00387	0.00405	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00379	0.00396	CcSEcCtD
Methylscopolamine bromide—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.00378	0.00395	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00375	0.00392	CcSEcCtD
Methylscopolamine bromide—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00374	0.00392	CcSEcCtD
Methylscopolamine bromide—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00372	0.00389	CcSEcCtD
Methylscopolamine bromide—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00371	0.00389	CcSEcCtD
Methylscopolamine bromide—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00369	0.00386	CcSEcCtD
Methylscopolamine bromide—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00366	0.00384	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00362	0.00379	CcSEcCtD
Methylscopolamine bromide—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.00361	0.00378	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00361	0.00378	CcSEcCtD
Methylscopolamine bromide—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.0036	0.00377	CcSEcCtD
Methylscopolamine bromide—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00357	0.00374	CcSEcCtD
Methylscopolamine bromide—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.00353	0.00369	CcSEcCtD
Methylscopolamine bromide—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.00348	0.00364	CcSEcCtD
Methylscopolamine bromide—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00347	0.00364	CcSEcCtD
Methylscopolamine bromide—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00346	0.00362	CcSEcCtD
Methylscopolamine bromide—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.00344	0.0036	CcSEcCtD
Methylscopolamine bromide—Headache—Indinavir—acquired immunodeficiency syndrome	0.00341	0.00357	CcSEcCtD
Methylscopolamine bromide—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.0034	0.00356	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.00335	0.00351	CcSEcCtD
Methylscopolamine bromide—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00332	0.00347	CcSEcCtD
Methylscopolamine bromide—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00327	0.00342	CcSEcCtD
Methylscopolamine bromide—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.00326	0.00342	CcSEcCtD
Methylscopolamine bromide—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00325	0.0034	CcSEcCtD
Methylscopolamine bromide—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00323	0.00338	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.00323	0.00338	CcSEcCtD
Methylscopolamine bromide—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00322	0.00337	CcSEcCtD
Methylscopolamine bromide—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.00314	0.00329	CcSEcCtD
Methylscopolamine bromide—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00313	0.00327	CcSEcCtD
Methylscopolamine bromide—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00308	0.00323	CcSEcCtD
Methylscopolamine bromide—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.00308	0.00322	CcSEcCtD
Methylscopolamine bromide—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00305	0.0032	CcSEcCtD
Methylscopolamine bromide—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00301	0.00315	CcSEcCtD
Methylscopolamine bromide—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.003	0.00314	CcSEcCtD
Methylscopolamine bromide—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00292	0.00306	CcSEcCtD
Methylscopolamine bromide—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00289	0.00303	CcSEcCtD
Methylscopolamine bromide—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00289	0.00303	CcSEcCtD
Methylscopolamine bromide—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00285	0.00298	CcSEcCtD
Methylscopolamine bromide—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00278	0.00291	CcSEcCtD
Methylscopolamine bromide—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00276	0.00289	CcSEcCtD
Methylscopolamine bromide—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00274	0.00287	CcSEcCtD
Methylscopolamine bromide—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.0027	0.00283	CcSEcCtD
Methylscopolamine bromide—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00266	0.00278	CcSEcCtD
Methylscopolamine bromide—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00262	0.00274	CcSEcCtD
Methylscopolamine bromide—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.0026	0.00272	CcSEcCtD
Methylscopolamine bromide—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00248	0.0026	CcSEcCtD
Methylscopolamine bromide—CHRM1—Circadian rythm related genes—CARTPT—acquired immunodeficiency syndrome	0.00129	0.0288	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.00112	0.0249	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.0011	0.0246	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000976	0.0218	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Regulation of Actin Cytoskeleton—ACTG1—acquired immunodeficiency syndrome	0.000929	0.0207	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000743	0.0166	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000687	0.0153	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000685	0.0153	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000678	0.0151	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Regulation of Actin Cytoskeleton—ACTG1—acquired immunodeficiency syndrome	0.000654	0.0146	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Regulation of Actin Cytoskeleton—ACTG1—acquired immunodeficiency syndrome	0.000652	0.0145	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Regulation of Actin Cytoskeleton—ACTG1—acquired immunodeficiency syndrome	0.000645	0.0144	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000591	0.0132	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000535	0.0119	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000523	0.0117	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000522	0.0116	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000517	0.0115	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00045	0.01	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000416	0.00929	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000415	0.00926	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000411	0.00917	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000407	0.00909	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000401	0.00896	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000398	0.00887	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000386	0.00861	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000381	0.00851	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000377	0.0084	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000375	0.00838	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000372	0.00829	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000365	0.00815	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000363	0.00809	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00033	0.00737	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000317	0.00708	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000316	0.00705	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000313	0.00698	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000311	0.00693	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000311	0.00693	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000289	0.00645	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000287	0.0064	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000286	0.00638	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000286	0.00637	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000283	0.00632	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000278	0.00621	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000272	0.00606	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000272	0.00606	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000272	0.00606	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000271	0.00604	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000269	0.00599	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000268	0.00598	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000268	0.00597	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000265	0.00592	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000257	0.00574	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000256	0.00572	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000255	0.0057	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000254	0.00568	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000254	0.00567	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000252	0.00562	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000252	0.00561	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000249	0.00555	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000237	0.00528	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000237	0.00528	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000236	0.00527	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000233	0.00519	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000232	0.00517	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000231	0.00516	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00023	0.00512	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000225	0.00503	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000219	0.00488	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000219	0.00488	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000218	0.00487	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000218	0.00487	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000216	0.00482	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000216	0.00482	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000213	0.00475	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000209	0.00466	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000207	0.00461	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000196	0.00437	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000195	0.00436	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000193	0.00431	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000186	0.00415	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00018	0.00402	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000177	0.00395	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000177	0.00394	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000175	0.0039	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000175	0.0039	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000174	0.00389	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000173	0.00385	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	0.000169	0.00376	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000167	0.00372	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000167	0.00372	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000166	0.00371	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000166	0.0037	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000166	0.0037	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000166	0.0037	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000164	0.00367	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000164	0.00367	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000164	0.00367	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000163	0.00363	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000162	0.00362	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000162	0.00362	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000161	0.00358	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000159	0.00354	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000158	0.00353	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000157	0.00349	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00015	0.00335	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000149	0.00333	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000148	0.0033	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000147	0.00328	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000147	0.00327	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000145	0.00324	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000143	0.0032	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000143	0.00319	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000142	0.00317	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000137	0.00305	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000137	0.00305	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000134	0.00298	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000134	0.00298	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000129	0.00288	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000127	0.00283	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000126	0.00282	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000125	0.00279	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000123	0.00275	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000121	0.00271	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000121	0.00271	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000114	0.00255	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000114	0.00254	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000113	0.00251	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000109	0.00243	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000102	0.00227	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000101	0.00224	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.0001	0.00224	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.0001	0.00224	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.0001	0.00223	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.98e-05	0.00223	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.92e-05	0.00221	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.88e-05	0.00221	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	9.76e-05	0.00218	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.61e-05	0.00214	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.61e-05	0.00214	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.58e-05	0.00214	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.58e-05	0.00214	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.49e-05	0.00212	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.49e-05	0.00212	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.41e-05	0.0021	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.41e-05	0.0021	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.38e-05	0.00209	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.38e-05	0.00209	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.29e-05	0.00207	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.29e-05	0.00207	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.24e-05	0.00206	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.16e-05	0.00204	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.1e-05	0.00203	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.09e-05	0.00203	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.06e-05	0.00202	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.97e-05	0.002	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	8.77e-05	0.00196	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.69e-05	0.00194	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.67e-05	0.00193	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.58e-05	0.00191	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.55e-05	0.00191	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.55e-05	0.00191	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.52e-05	0.0019	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.52e-05	0.0019	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.44e-05	0.00188	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.44e-05	0.00188	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.43e-05	0.00188	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.32e-05	0.00186	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.63e-05	0.0017	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	7.26e-05	0.00162	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.17e-05	0.0016	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.17e-05	0.0016	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.16e-05	0.0016	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.14e-05	0.00159	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.07e-05	0.00158	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.05e-05	0.00157	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.03e-05	0.00157	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.96e-05	0.00155	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.88e-05	0.00153	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.85e-05	0.00153	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.5e-05	0.00145	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.48e-05	0.00145	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.45e-05	0.00144	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.43e-05	0.00143	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.42e-05	0.00143	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.41e-05	0.00143	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.39e-05	0.00142	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.37e-05	0.00142	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.32e-05	0.00141	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.94e-05	0.00133	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.92e-05	0.00132	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.86e-05	0.00131	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.86e-05	0.00131	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.84e-05	0.0013	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.78e-05	0.00129	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.46e-05	0.00122	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.37e-05	0.0012	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.37e-05	0.0012	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.35e-05	0.00119	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.3e-05	0.00118	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.29e-05	0.00118	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.05e-05	0.00113	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.05e-05	0.00113	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.03e-05	0.00112	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.03e-05	0.00112	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.98e-05	0.00111	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.98e-05	0.00111	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.92e-05	0.0011	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.81e-05	0.00107	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.84e-05	0.000857	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.83e-05	0.000854	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.79e-05	0.000846	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.78e-05	0.000844	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.77e-05	0.000842	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.74e-05	0.000833	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.73e-05	0.000832	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.72e-05	0.000829	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.68e-05	0.000821	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.46e-05	0.000772	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.45e-05	0.00077	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.42e-05	0.000762	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.38e-05	0.000755	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.37e-05	0.000753	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.34e-05	0.000746	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	2.94e-05	0.000656	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.84e-05	0.000634	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.83e-05	0.000631	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2e-05	0.000446	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.99e-05	0.000445	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.99e-05	0.000444	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.98e-05	0.000443	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.97e-05	0.00044	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.96e-05	0.000438	CbGpPWpGaD
Methylscopolamine bromide—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.67e-05	0.000372	CbGpPWpGaD
Methylscopolamine bromide—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.18e-05	0.000262	CbGpPWpGaD
Methylscopolamine bromide—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.17e-05	0.000261	CbGpPWpGaD
Methylscopolamine bromide—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.16e-05	0.000259	CbGpPWpGaD
